TransMedics Group, Inc. (NASDAQ:TMDX) Short Interest Update

TransMedics Group, Inc. (NASDAQ:TMDX) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,430,000 shares, a growth of 30.9% from the October 15th total of 6,440,000 shares. Based on an average daily volume of 1,390,000 shares, the short-interest ratio is currently 6.1 days.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the sale, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The trade was a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,958 shares of company stock valued at $5,230,528. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank boosted its position in shares of TransMedics Group by 6.7% in the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after acquiring an additional 70 shares during the period. Pitcairn Co. lifted its position in shares of TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after acquiring an additional 78 shares during the period. Harbour Capital Advisors LLC increased its position in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after purchasing an additional 81 shares during the period. Signaturefd LLC grew its stake in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares in the last quarter. Finally, Arizona State Retirement System raised its position in shares of TransMedics Group by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after buying an additional 186 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TMDX has been the topic of several research reports. Robert W. Baird cut their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. Needham & Company LLC lowered their price objective on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a report on Tuesday, October 29th. Oppenheimer reduced their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a report on Tuesday, October 29th. Canaccord Genuity Group decreased their price objective on TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Finally, JPMorgan Chase & Co. dropped their target price on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Buy” and a consensus target price of $144.80.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded down $7.88 on Friday, hitting $80.48. The company had a trading volume of 2,305,980 shares, compared to its average volume of 969,652. The stock has a 50 day moving average price of $125.63 and a 200 day moving average price of $139.09. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08. TransMedics Group has a 1-year low of $63.85 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm’s quarterly revenue was up 63.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.12) EPS. Analysts expect that TransMedics Group will post 1.07 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.